Fibrinolysis is the process by which fibrin is degraded during blood coagulation. Hyperfibrinolysis is divided into primary (caused by factors such as increased activators of fibrinolytic enzymes, surgical trauma, etc.) and secondary (caused by factors such as thrombophilia, etc.). Primary requires antifibrinolytic treatment which can be given by aminocaproic acid, etc., while secondary requires treatment of the primary disease, heparin, and other treatments. 1. Fibrin is degraded in the later stages of blood clotting, but if fibrin is degraded too early or too much, which is what we call hyperfibrinolysis, it can lead to bleeding. Hyperfibrinolysis is divided into primary and secondary. Primary refers to the abnormal activity of the fibrinolytic system due to the increase of fibrinogen activator, surgical trauma, etc., while secondary refers to the abnormal activity of the fibrinolytic system secondary to certain diseases such as thrombophilia. 2. Primary hyperfibrinolysis requires antifibrinolytic treatment, drugs include aminocaproic acid, aminotranexamic acid, etc., its adverse effects include dizziness, headache, etc., patients with thrombophilia are prohibited or used with caution. 3. Secondary hyperfibrinolysis is mostly due to excessive coagulation, resulting in the production of a large number of fibrin, which causes hyperfibrinolysis, the need to treat the primary disease, can be applied to heparin anticoagulant therapy, as well as transfusion of fresh plasma and so on. Adverse effects of heparin include spontaneous bleeding, etc. It is contraindicated in patients with severe hypertension. Hyperfibrinolysis needs timely treatment to avoid delay.